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Abstract
Small molecules have been identified as potential therapeutic agents for lysosomal storage diseases (LSDs), inherited
metabolic disorders caused by defects in proteins that result in lysosome dysfunctional. Some small molecules function
assisting the folding of mutant misfolded lysosomal enzymes that are otherwise degraded in ER-associated degradation.
The ultimate result is the enhancement of the residual enzymatic activity of the deficient enzyme. Most of the high
throughput screening (HTS) assays developed to identify these molecules are single-target biochemical assays. Here we
describe a cell-based assay using patient cell lines to identify small molecules that enhance the residual arylsulfatase A (ASA)
activity found in patients with metachromatic leukodystrophy (MLD), a progressive neurodegenerative LSD. In order to
generate sufficient cell lines for a large scale HTS, primary cultured fibroblasts from MLD patients were transformed using
SV40 large T antigen. These SV40 transformed (SV40t) cells showed to conserve biochemical characteristics of the primary
cells. Using a specific colorimetric substrate para-nitrocatechol sulfate (pNCS), detectable ASA residual activity were
observed in primary and SV40t fibroblasts from a MLD patient (ASA-I179S) cultured in multi-well plates. A robust
fluorescence ASA assay was developed in high-density 1,536-well plates using the traditional colorimetric pNCS substrate,
whose product (pNC) acts as ‘‘plate fluorescence quencher’’ in white solid-bottom plates. The quantitative cell-based HTS
assay for ASA generated strong statistical parameters when tested against a diverse small molecule collection. This cell-
based assay approach can be used for several other LSDs and genetic disorders, especially those that rely on colorimetric
substrates which traditionally present low sensitivity for assay-miniaturization. In addition, the quantitative cell-based HTS
assay here developed using patient cells creates an opportunity to identify therapeutic small molecules in a disease-cellular
environment where potentially disrupted pathways are exposed and available as targets.
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Introduction
In the drug discovery process, the use of cell-based assays for
high throughput screening (HTS) has become increasingly
common as targets are presented in a more relevant biological
context than classical in vitro biochemical assays [1]. Cell-based
HTS assays also allow the identification of compounds that cross
cell membranes, and reach specific cellular compartments,
providing simultaneously cell permeability and cytotoxicity
information at an earlier stage of the screening [2]. However, in
most cellular HTS assays, cells utilized are usually not disease
relevant. Thus, the use of patient-derived cell lines for HTS
campaign brings considerable advantages when comparing with
the traditional single target biochemical assays. Cellular assays
using patient cells provide a unique opportunity to assess a target
protein and/or pathway in the context of potentially disrupted
biochemical and/or signaling pathways secondary to the disease
process. In addition, this pathogenic in cellulo setting permits the
evaluation of multiple intervention points, which are potentially
altered in the disease, as opposed to commonly used cell-
expression systems of a specific protein target or a predefined
step of a purified or recombinant protein-based assay.
Recently, small molecules have become an attractive approach
for the treatment of lysosomal storage diseases (LSDs), inherited
metabolic disorders resulting from mutations in genes encoding
proteins crucial for lysosomal function [3]. The almost 60 LSDs
are individually rare, however, collectively, their incidence is about
1/7,000, making these disorders an important health problem
worldwide [4]. Despite the important advances in treatment for
LSDs, only six have FDA-approved drugs that control or attenuate
some of the disease-related symptoms [5]. As most of these drugs
are recombinant enzymes that are unable to cross the blood-brain
barrier (BBB), only non-neurological symptoms are treated. A
considerable number of HTS assays have been developed to
identify small molecules (,500 Da), which are more likely to cross
the BBB. Some of them function as pharmacological chaperones
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enzymes by physical interactions that assist their folding [6,7,8].
Most missense mutations encode misfolded lysosomal enzymes
that are partially functional as the majority of these mutant
proteins are degraded early by the ER-associated degradation
(ERAD) pathways [9]. Most of HTS assays developed to identify
PCs have been based on single-target biochemical assays
[10,11,12]. Based upon these observations, a cell-based HTS
assay will allow the identification of small molecules that function
not only as PCs, but also others that enhance the residual
lysosomal enzymatic activity by acting in different molecular
pathways that result in increased levels of the mutant, but still
partially functional enzyme in the lysosomal compartment [13].
Here we demonstrate the development of a cell-based HTS
assay in 1,536-well plates utilizing cultured skin fibroblasts from a
patient with metachromatic leukodystrophy (MLD), a LSD caused
by deficiency of arylsulfatase A (ASA), resulting in severe
demyelination secondary to the accumulation of sulfatide lipid in
myelin [14]. No specific treatment is currently available for this
neurological LSD. The main goal of the study was to generate a
reliable cell-based HTS assay to screen chemical compound
collections to identify small molecules with therapeutic potential
for MLD. We developed a novel patient cell-based fluorescent
HTS assay taking advantage of the ability of para-nitrocatechol
(pNC), product of desulfation of a colorimetric substrate for ASA,
to quench fluorescence emitted from white solid-bottom multi-well
plates. This method increases considerably the sensitivity and
statistical robustness of the HTS assay for ASA when testing it
against a small compound collection library.
Results
Establishment and characterization of SV40-transformed
fibroblasts from MLD patients
Primary skin fibroblasts from patients with several LSDs are one
of the most reliable cell lines to study LSDs [15]. Most key
biological concepts in LSDs have been discovered in cultured skin
fibroblasts from patients with diverse types of these genetic diseases
[16,17]. Cultured skin fibroblasts from patients with MLD were
assembled and the ARSA gene sequenced to determine mutations
and potential polymorphisms that commonly affect the ASA
activity [14]. In order to have sufficient cells for the HTS assays,
cultured skin fibroblasts were transformed using large T antigen
from simian virus (SV40). Primary cells cultured to confluence in
75 cm
2-flasks, when harvested and re-suspended in a specific
medium volume, generated a concentration of 200–300 cells/
microL. When SV40t cells were grown to confluence in the same
flasks, a higher concentration of 1,000–2,000 cells/microL was
observed after culture, trypsinization and res-suspension under the
same conditions. The increased cell number of cultured SV40t cell
lines is explained by their growth being less inhibited by cell
contact, which is consistently observed in cultured primary
fibroblasts. In SV40t fibroblasts, ASA enzymatic activity is
conserved in both controls with wild type ASA (ASA-WT) and
MLD patient cells with mutant ASA that retain residual ASA
activity. After SV40 transformation, the difference in ASA activity
between controls and MLD patients is also preserved. A
comparable level of residual ASA activity is seen in SV40t
fibroblasts from patients with late onset forms of MLD (Fig.1A and
1B). Additionally, the morphology of SV40t cells is altered to a
typical polygonal shape (Fig.1C), in contrast with the fusiform-
shape of primary lines (Fig.1D). The level of other lysosomal
enzymes, such as total beta-hexosaminidase (Hex) and beta-
galactosidase, from SV40t MLD patient (ASA-D355V/
c.495+1C.A) and control (ASA-WT) cells were not significantly
different from the levels obtained from the original and
corresponding primary cell lines (Fig.1E).
When treating cells with artificial sulfatide analog (N-lissamine
rhodaminyl-(12 aminododecanoyl)cerebroside 3-sulfate (NBD-sul-
fatide), conjugated to free lipid albumin [18], increased accumu-
lation of this fluorescent sulfatide, is observed in primary and as
well as SV40t MLD patient cell lines in comparison to respective
controls (Fig.2). This result indicates that conservation of the
impaired degradation of the NBD-sulfatide in ASA deficient cells
after SV40 transformation.
Exploring the fluorescence properties of white solid-
bottom plates using the classical colorimetric substrate
for ASA
Under specific assays conditions, the classical para-nitrocatechol
sulfate (pNCS) colorimetric substrate permits the distinction of
ASA activity from arylsulfatase B (ASB), another lysosomal
sulfatase [19,20]. However, the use of a colorimetric substrate
with its inherent low sensitivity limits miniaturization of this ASA
assay into higher density microplates. Traditionally, colorimetric
assays are not readily scalable to small volumes required for
miniaturization into high dense plates [21]. A method was
described to miniaturize colorimetric assays to 1,536-well format
using fluorescence properties of white solid-bottom microplates
[22]. In this fluorescence- quench absorbance assay, absorbance is
measured by the decrease of fluorescent signal from white material
of the plate at an excitation or emission wavelength that matches
the absorbance maximum of the colored reaction product. Based
on this principle, experiments were performed to determine
optimal capturing fluorescence of white solid-bottom 1,536-well
plates. The desulfation of pNCS by ASA generates para-
nitrocatechol (pNC) product, which has an orange to red color
(Fig.3A). Given the fluorescence properties of white solid-bottom
1,536-well plates and the pNC absorbance, quenching of emitted
fluorescence by pNC, was tested using increasing concentrations of
pNC product at two conditions: excitation 430 nm and emission
525 nm and excitation 525 nm and emission at 598 nm
(Figs.3B and 3C). In each of these two assays, the pNC maximal
absorbance ,515–520 nm matched with emission (525 nm;
Fig.3B) or excitation (525 nm; Fig.3C). At excitation 430 nm
and emission 525 nm, the substrate pNCS showed to quench the
fluorescence emitted by white solid-bottom plate. Therefore, less
plate fluorescence remains to be quenched by the increasing
concentrations of the product pNC and decreasing concentrations
of pNCS in a mixed pNCS/pNC solution (Fig.3B). However,
using a red-shifted wavelength (525/598 nm - excitation/emis-
sion), pNCS (substrate) no longer quenches plate fluorescence,
allowing pNC (product) to quench it gradually as its concentra-
tions increases (Fig.3C). The fluorescence reading parameters were
set at excitation 525 nm and emission 598 nm in order to obtain
the optimal fluorescence quench absorbance with the pNC
product generated from ASA reaction against colorimetric
substrate pNCS.
Miniaturization into 384-well plates using SV40
transformed fibroblasts
The objective of developing a cell-based HTS assay for ASA is
to treat cultured fibroblasts from a MLD patient with a small
molecule collection for a specific time period, and subsequently to
measure the resultant effect on the residual ASA activity.
Preliminary experiments done using primary fibroblasts cultured
in 96-well plates demonstrated an encouraging assay-window
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fibroblast cell line (ASA-I179S), which shows the highest ASA
residual activity (Supporting Information S1 and Fig.S1). SV40t
fibroblasts from both controls and the MDL patient generate
higher absorbance signals than primary fibroblasts (Fig.S2). SV40t
cells were then cultured in white solid-bottom 384-well plates,
assayed with pNCS substrate and fluorescence was measured at
excitation/emission pair 525/598 nm in a multiple-well plate
Figure 1. Biochemical and morphological comparison between primary and transformed cultured skin fibroblasts. Primary and SV40-
transformed (SV40t) skin fibroblasts were culture in 75 cm
2 flasks up to confluence before being harvest to obtain cell lysates to perform ASA activity
assays. (A) ASA enzymatic activity of primary skin fibroblast, control with wild type ASA (ASA-WT) and three MLD patient cell lines with different ARSA
mutations. Each of these cell lines carries a previously described mutant ASA with a residual enzymatic activity (I179S, P426L, D335V). ASA activity is
expressed in nmoles of pNC per hour and standardized by protein concentration. (B) ASA activity from SV40t fibroblasts showed comparable ASA
activity with primary cell lines. (C) Cell morphology of primary skin fibroblasts showed the classical fusiform shape. The SV40t counterparts (D) show
distinguishable polygonal shape. (E) The ratio of enzymatic activity of two other lysosomal enzymes beta-galactosidase and total beta-
hexosaminidase are shown. Both the control (ASA-WT; dark gray) and MLD patient cells (ASA-D355V/c.959+1C.A; light gray) showed a ratio close to
1.
doi:10.1371/journal.pone.0029504.g001
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optical density (OD), calculated as OD=2log(sample/blank), where
sample is the signal obtained from a well containing cells (control or
MLD cells), culture medium, pNCS substrate buffer and stop
reaction solution (assay reagents); blank is the mean from signals
from wells containing no cells, only cultured media and assay
reagents (Fig.4). Blank references generate higher fluorescence
signals (405.769.5), as no colorimetric product (pNC) is formed
from the desulfation of pNCS. Lower fluorescent signals
(105.5615.8) were observed from wells with control SV40t
(ASA-WT) cells as they produce more colorimetric pNC product
that quenches fluorescence emitted from the bottom of the plate.
Cultured SV40t MLD patient fibroblasts (ASA-I179S) generate
low levels of pNC product (due to ASA residual activity), resulting
in elevated fluorescent signals (354.1613.7), but still lower than
blank reference. The calculated OD increased the assay-window
between control (ASA-WT) and MLD patient (ASA-I179S)
fibroblasts (Fig.4B and 4D). A ‘‘sister plate’’ was prepared in
black clear-bottom 384-well plate to monitor cell status of
confluence and measure absorbance (Fig.4A and C). In order to
evaluate the ideal cell number to seed in each well, different cell
numbers were placed into columns of a 384-well plate. Seeding
approximately 40610
6 cells/well, the highest absorbance signals
in both control (ASA-WT) and MLD patient (ASA-I179S) cells
were obtained. As in previous assays, ASA assays performed in
white solid-bottom 384-well plates with a fluorescence reading
(525/598 nm for excitation/emission) showed a clear and
significant difference between SV40t controls and MLD patient
fibroblasts (Fig.4E and 4F).
1,536-well miniaturization and pilot screening assay
against a small drug collection
Based on the ASA assay parameters developed in 384-well
plates, initial experiments were done in 1,536-well plates. In these
latter plates, on average 8610
3 cells were seeded per well. Table 1
describes the optimal conditions for the ASA assay in 1,536-well
Figure 2. NBD-sulfatide assay in primary and SV40 transformed cultured fibroblasts. Primary and SV40-transformed (SV40t) culture
fibroblasts from MLD patient (c.459+1G.A/E484L) were exposed over 24hs to 10 nmoles of albumin-conjugated of NBD-sulfatide (see Methods). The
ability of ASA enzymatic activity to degrade the exogenous fluorescent-labeled sulfatide, NBD-sulfatide, can distinguish MLD patient primary
fibroblasts (ASA-MUT) (B) from controls (A) with normal ASA-WT enzymatic activity. SV40t fibroblasts from MLD patient (D) also demonstrated
elevated accumulation of NBD-sulfatide when compared with SV40t control fibroblasts with normal ASA activity (C).
doi:10.1371/journal.pone.0029504.g002
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a pilot screening was performed utilizing the Library of
Pharmacologically Active Compounds (LOPAC) containing
1,280 small molecules. The design and time-line of the HTS
assay is depicted in figure 5. In the HTS assay, only SV40t cells
from MLD patient (ASA-I179S) and control (ASA-WT) were used.
In each 1,536-well plate, a control cell line (ASA-WT) was seeded
in columns 2, 3, 46 and 47, as no pharmacological chaperone
exists for ASA to be used as a positive control for the HTS assay.
Columns 4 and 45 contain MLD patient cells only treated with
DMSO. Columns 5 to 44 of these high-density plates is known as
the ‘‘compound area’’, which includes 1,280 wells with cultured
MLD (ASA-I179S) patient cells (Fig.5B). Thus, one 1,536-well
plate accommodates the entire LOPAC library at one small
molecule/well (Fig.5A). Using seven 1,536-well plates, each with
different concentrations of the LOPAC compounds (7610
23,
36610
23, 0.18, 0.92, 4.5, 22.8 and 114.2 microM), and an
additional plate treated only DMSO (solvent of LOPAC
compounds), cells were treated for 48 h prior to performing the
ASA assay (Fig.6A and 6B). The concentrations used were based
on earlier quantitative HTS assays [23]. False-positives were
defined as OD signals $3 S.D. above the OD mean obtained from
the wells containing MLD patient cells. No false-positives were
observed in the plate treated only with DMSO (Fig.6A). The
coefficients of variance (CVs), Z’ factors, signal-to-background
ratios of ASA activity (control/MLD patient cells) are shown in
Figure 3. Development of a fluorescence-quench absorbance assay for ASA using a colorimetric substrate in white solid-bottom
1,536-well plates. (A) Basis of the fluorescence-quench absorbance assay. The desulfation of pNCS by ASA generates pNC, a colorimetric product,
whose optimal absorbance is detectable at 515 nm. Thus, the reaction is performed in clear-bottom (transparent) microplates to measure trans-
absorbance. Since white plastic solid-bottom plates have fluorescence properties [22], when an excitation light is directed to white solid-bottom
microplates, emission light can be detected by epi-absorbance (A). The green arrow represents the fluorescence signal emitted from of solid-bottom
of the well of a plate. Therefore, the generated pNC product can be used to quench the emission of the light from the bottom of each well in white
solid-bottom plates. Based on this principle, the optimal concentrations of pNCS (yellow well) and pNC (brown well) were tested in white solid-
bottom 1,536-well plates. Solutions with increasing %concentrations of 0.2 mM (pink lines) and 0,4 mM (red lines) of pNC were used. A pNC+pNCS
mixed solution with decreasing %concentrations of 0.2 mM pNCS substrate and increasing %concentrations of 0.2 mM pNC product was used to
simulate the effects of ASA over the pNCS substrate. (B) At excitation 430 nm and emission 525 nm (close to pNC absorbance, 515 nm), the pNCS
substrate quenches fluorescence from the white solid-bottom plate showing an OD of ,0.4 at its initial concentration0.2 mM; yellow well with
decreased green arrow). Consequently, a flat line with increasing of %concentrations of pNC product was generated (yellow line). (C) However, at
excitation 525 nm (close of 515 nm) and emission 598 nm, pNCS no longer quenches the fluorescence from white solid-bottom plate (yellow well
with increased green arrow), demonstrating an increasing OD signal with the increase of %pNC (product) and decreased %pNCS (substrate) in the
mixed solution of pNCS+pNC. This pNC+pNCS solution (yellow line) overlaps with the solution containing only pNC at 0.2 mM (pink line).
doi:10.1371/journal.pone.0029504.g003
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treated only with DMSO, the plates treated with the lowest
(7610
23 microM) and highest (114.2 microM) LOPAC concen-
trations. The scatter plot results from the remaining five
concentrations of LOPAC (0.92, 4.5, 22.8 and 114.2 microM)
are shown in Figure S2.
Concentration-response curve analysis of cell-based HTS
for ASA
In the developed cell-based quantitative HTS assay for ASA,
increases in the OD signals can represent enhancements of
residual ASA enzymatic activity in MLD cultured cells (ASA-
I179S). Based on the quantitative nature of the screen, in which
seven different concentrations of the LOPAC were tested, the
selection of candidate compounds is based on the concentration
response-curves [23]. The classification of the concentration-
response curves was described earlier (Table S1) [23]. The results
showed a selective and low ‘‘hit’’ rate in the developed HTS assay.
In the concentration-curve analysis, four candidate compounds
showed best concentration-response curves classified as class 2.2,
which are defined as ‘‘partial curves’’ (containing one asymptote)
with r
2$0.9 and efficiency ,80% (% OD enhancement) [23]
Figure 4. Testing the fluorescence-quench absorbance assay as a throughput assay for ASA activity in cultured cells. (A) In cultured
SV40t fibroblasts from control (ASA-WT) and MLD patient (ASA-I179S), the absorbance ASA assay (515 nm) was tested and showed robust results in
black clear-bottom 384-well plates. Each bar corresponds to the mean signal from 16 wells (one plate column). In 384-well white solid-bottom plates,
these cultured SV40t fibroblasts showed comparable results were observed (B). Optical density (OD) calculation is described in Methods section. Inter-
leaved 384-well plate assays also showed similar results for both ASA absorbance (C) and fluorescence-quench absorbance (D). In a 384-well plate,
SV40t fibroblasts from control and a MLD patient were seeded at different numbers per well (E). Using the 15 mM of pNCS substrate concentration in
the substrate/lysis buffer, seeding 40610
6 cells/well showed the best results of spectrophotometric assays. By reducing the number of cells in each
well, 20610
6,1 0 610
6 and 5610
6, correspondent and equivalent reductions of absorbance signals were observed. (F) The same pattern of results was
noted when culturing the same number of cells in a white solid-bottom 384-well plate. However, the optical density (O.D.) measurements read at
excitation/emission pair of 525/595 nm from white solid-bottom plate showed improvement in the assay-window between ASA enzymatic activity
from SV40t control and MLD patient fibroblasts.
doi:10.1371/journal.pone.0029504.g004
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I179S - blue) and from control (ASA-WT - yellow) in a 1,536-well plate. (B) The time-line of events of this cell-based HTS assay for ASA. A library of
1,280 small-molecules at seven different concentrations from 7610
23 to 114.2 microM was used to perform a pilot HTS assay. A total of eight 1,536-
well plates in the same format were assayed including one plate with cells treated with DMSO (solvent of compounds) and seven other plates for
each of the LOPAC concentration tested.
doi:10.1371/journal.pone.0029504.g005
Table 1. Cell-based HTS assay for ASA protocol.
Step Action Volume
Time in Total Assay
or Timeframe Description
1 Seeding cells 4 microL 0 SV40t cell lines from MLD patient and
control are seeded in 1,536-well plate
2 Cell Incubation - 6
th hour 37uCa n d5 % C O 2
3 Pin dispense 46 nL ,6 h LOPAC compound plates in DMSO
4 LOPAC Treatment - 48 h 37uCa n d5 % C O 2
5 ASA assay 4 microL 54
th hour Substrate/lysis buffer – pNCS(1 mM)/TX-100(1%) – final
[pNCS]=0.5 mM
6 Substrate Incubation - 14 h ASA assay incubation at room temperature
7 Dispense 2 microL 68
th hour Stop solution – NaOH (5N)
8 Fluorescent Readout - 68
th hour CCD-based Viewlux reader
ASA, arylsulfatase A; CCD, charge-coupled device, HTS, high throughput screen; NaOH, sodium hydroxide; LOPAC, library of pharmacologically active compounds; MLD,
metachromatic leukodystrophy; pNCS, p-nitrocatechol sulfate; SV40t, SV-40 transformed.
doi:10.1371/journal.pone.0029504.t001
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fluorescent dyes: ruthenium red, which absorbs light at
,533 nm and reactive blue, which absorbs at 605 nm
(Fig.7A and 7B). Since in this HTS assay for ASA, fluorescence
is measured at excitation 525 nm and emission 595 nm, these two
compounds are quenching either excitation (ruthenium red) or
emission (reactive blue) used for the HTS assay. Therefore, the
absorption and emission wavelengths of the two compounds
explain the reason why they were identified as candidates. Two
other candidate small molecules also showed concentration-
response curves of class 2.2 (Fig.7C and 7D). One of them is
also colorimetric compound (JFD00244). In order to exclude the
potential fluorescent and colorimetric small molecules, two
additional HTS assays were performed: one adding the LOPAC
compounds just before dispensing the substrate/lysis buffer (pre-
ASA assay) and another adding LOPAC compounds after
stopping the assay reaction (post-ASA assay). These HTS were
performed in 1,536-well plates with the same disposition of SV40t
cells. The four highest concentrations of LOPAC (0.92, 4.5, 22.8
and 114.2 microM) were used to identify colorimetric and
fluorescent compounds (Fig.8). These two assays were confirma-
tory and revealed that the color small molecules ruthenium red,
reactive blue, JFD00244, 6-OH-DL-Dopamine (curve class 2.2)
present increases of OD values correlating with increases of their
concentrations (Fig.8A–D). Other compounds including the
tyrphostin AG 538 and AG 808 (curve class 2.4) also showed
the same pattern of increases of OD values (Fig.8E and 8F).
A few other small molecules showed concentration-curves
(curve class 2.4) with less optimal fitting (r
2#0.9) and lower
efficiency (Min. 2 80%) (Fig.7E–H). In the curve analysis HTS,
these small molecules generated subtle increases of OD values (10–
15% from mean OD) (Fig.7D–H). When tested in primary
cultured fibroblasts from MLD patient (ASA-I179S) and controls
(ASA-WT), these small molecules with curve class 2.4 failed to
produce any significant enhancement of ASA activity in primary
control (ASA-WT) and MLD patient (ASA-I179S) fibroblasts
(Fig.9C–F). Some of these compounds promoted significant
reduction of ASA activity in both control and MLD patient
fibroblasts (Fig.9A, 9D and 9C). Cell viability assays confirmed the
cytotoxicity of these small molecules (Table S2).
Discussion
Here we report a patient cell-based HTS assay for the
identification of potential drug candidates for a LSD. The
utilization of a representative patient cell line already in the
primary stage of HTS offers considerable advantages in the
discovery of small molecules of potential disease relevance. The
use of patient cells displays a ‘‘disease cellular environment’’ where
numerous disrupted molecular pathways secondary to the primary
Table 2. Statistical parameters of the quantitative cell-based HTS for ASA.
LOPAC concentration (microM) CV (%) Z’ Factor Signal/background
Control MLD
DMSO 1.03 1.94 0.45 12.962.2
7610
23 0.61 2.58 0.64 20.061.5
36610
23 0.42 2.66 0.70 20.061.1
0.18 0.50 1.31 0.68 11.461.4
0.9 0.48 1.97 0.69 16.161.2
4.5 0.39 4.49 0.70 30.860.8
22.8 0.59 2.26 0.57 13.261.0
114.2 0.58 4.54 0.54 20.160.81
ASA, arylsulfatase A; CV, coefficient of variance; DMSO, dimethyl sulfoxide; HTS, high throughput screen; LOPAC, Library of Pharmacologically Active Compounds; MLD,
metachromatic leukodystrophy: SD, standard deviation.
doi:10.1371/journal.pone.0029504.t002
Figure 6. Scatter plot from the quantitative cell-based HTS assay for ASA using the LOPAC library. In each panel, columns 2, 3, 46 and
47 depict OD values from wells with control cells (ASA-WT), which were not exposed to small molecules. OD values from MLD patient fibroblasts
(ASA-I179S) treated only with DMSO were located in columns 4 and 45. SV40t MLD patient fibroblasts were seeded in columns 5 to 44. The 1,536-well
plates treated with DMSO (0.57%) (A), lowest (7610
23; B) and highest (114.2 microM; C) concentrations of LOPAC are shown. Small molecules,
demonstrating increased ODs in the plot C, were studied further in the curve analysis.
doi:10.1371/journal.pone.0029504.g006
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genic cascades have been shown to occur and have implications in
the molecular mechanism of several LSDs [24]. Several cell-based
assays have been developed for HTS including second messenger
mobilization after GPCR activation [25], reporter gene assays [26]
and phenotypic assays for cellular processes (e.g., cell migration
[27], cytokinesis [28]). However, none of the previously described
HTS assays utilized patient-derived cells. Another advantage of
patient cell-based HTS assays is that several potentially altered
molecular pathways can be exposed to the tens or hundred
thousands of small molecules from a specific library. Therefore,
novel molecular pathways that are indirectly interacting with the
target protein and/or pathway of interest are amenable to be
identified and subsequently used as therapeutic targets. An
algorithm summarizing the development of the HTS assay here
described is depicted in figure 10.
To have access to sufficient number of cells for a large-scale
HTS assay, the transformation using pSV3 plasmid carrying the
SV40 large T-antigen was required. The SV40t skin fibroblasts
from MLD patients conserve the deficiency of ASA as observed in
transformation of primary fibroblasts from other LSDs [29]. The
SV40t fibroblasts maintain the same level of ASA activity along
with other lysosomal enzymes as observed in primary cells (Fig.1).
In cultured primary fibroblasts, patients with late-onset forms of
MLD have up to 10% of residual ASA activity [30]. SV40t
fibroblasts from MLD patients present consistently the same
residual ASA activity levels when compared to SV40t control cells
with ASA-WT activity (Fig.1). Since pseudo-polymorphism alleles
(p.1049A.G; p.96A.G) are common in different ethnic groups
[31] resulting in lower ASA activity, ARSA genes of controls were
also sequenced and confirmed wild-type ARSA sequence. The
SV40t cells have different morphology from spindle-shaped form
of primary cells as predicted (Fig.1). As demonstrated in primary
cultured fibroblasts, SV40t MLD patient cell lines also present
elevated accumulation of the fluorescent NBD-sulfatide after 24 hs
exposure in comparison to correspondent SV40t controls (Fig.2).
The ultimate goal of the cell-based HTS for ASA is to identify
small molecules that enhance the residual ASA activity found
patients with MLD. Therefore, the readout the HTS assay is based
on detectable residual ASA activity in MLD cultured fibroblasts.
The candidate small molecules are predicted to interact directly
with the mutant ASA, functioning as PCs, i.e. binding to the
misfolded ASA and assisting its folding [9]. Since the developed
HTS assay is a cell-based assay, other classes of small molecules
that interact with different elements of molecular pathways
involved in the folding, trafficking, maturation or degradation of
the misfolded ASA mutant resulting in enhancements of its
residual activity, will also be identified. During the throughput
assay development, the use of pNCS colorimetric substrate
detected measurable residual ASA activity from the MLD patient
cells with ASA-I179S. This specific MLD patient cell line was
chosen, as it is one of the most frequent ARSA mutations with the
highest residual ASA activity (Fig.1 and 3) [32]. Approximately 80
missense mutations have been identified in MLD patients with
residual ASA catalytic activity. About half of the missense
mutations lead to arrest of the mutant protein in the ER due to
misfolding [33]. Initially, assay conditions adjusting the optimal
substrate concentration were developed in 96-and 384-well plates
(Fig.S1). In order to streamline the protocol, the step of media
removal was eliminated and consequently the use of non-phenol
Figure 7. Concentration-response curve analysis obtained from the quantitative cell-based HTS assay for ASA against LOPAC
library. In the cell-based HTS for ASA using LOPAC concentrations ranging 7610
23 - 114.2 microM, two compounds, ruthenium red (A) and reactive
blue (B), showed concentration-response curve of class 2.2 (partial curve; r
2$0.9; efficacy#80%). Other two small molecules, JFD00244 (C) and 6-OH-
DL-Dopamine (D) also presented concentration-response curves of class 2.2. Four small molecules, methoxyverapamil HCl (E), DL-erythro-
dihydrosphingosine (F), 6-OH-melatonin (G) and I-Me-Tyrphostin AG 538 (H) showed concentration-response curves of class 2.4 (partial curve; r
2#0.9;
efficacy Min. 280%).
doi:10.1371/journal.pone.0029504.g007
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detergent was used to assure cell lysis (Fig.3).
The miniaturization of the assay into small volumes (,10
microL) is required for high-dense microplates. In this setting,
fluorescence and luminescence assays are preferable given their
higher signals and consequently superior sensitivity [34,35,36].
The colorimetric substrate pNCS produced robust data up to 384-
well plates (Fig.4A and 4C). In order to overcome the limitation of
the low sensitivity of the colorimetric substrate, the fluorescent
properties from white solid-bottom polystyrene plates and the
characteristics of pNC product were explored. In this study, the
colorimetric product pNC (generated from ASA desulfation of
pNCS) quenches the intrinsic fluorescence of white solid-bottom
plate at a specific emission and excitation pair 525/598 nm. This
ability of the ASA product pNC to quench the white plate
fluorescence allows the use of epi-absorbance mode to measure the
ASA activity of SV40t MLD patient and control fibroblasts
cultured in these white solid-bottom plates (Fig. 3A). In
preliminary studies in 384-well plates, higher fluorescence signals
were obtained from blank wells (no pNC product generated) in
comparison to fluorescence signals from wells with control
(significant pNC product generated by ASA-WT) and MLD
patient fibroblasts (small pNC product generated by residual ASA-
I179S). The resultant OD ratio generates higher control/patient
ratios than those obtained from the colorimetric absorbance assay
(Fig.4B and 4D). When miniaturized to white solid-bottom 1,536-
well plates, adapting similar conditions developed in 384-well
plates, the fluorescence-quench absorbance for ASA assay showed
consistent results.
In order to test the robustness of the cell-based HTS assay using
an MLD patient line, a small and structurally diverse chemical
compound library was chosen for the pilot screening. LOPAC
contains representatives of major target classes of small molecules,
which are all ,500 Da and solubilized in DMSO. LOPAC is often
used to determine ‘‘hit’’ rates and statistical parameters of HTS
assays, before embarking on screening larger libraries. The results
from the LOPAC pilot-screen revealed the robustness of the MLD
patient cell-based HTS assay as measured by Z’ scores .0.5
(Table 2). The main reason to perform a quantitative HTS with
LOPAC library was to select small molecules that function as
enzyme enhancement agents (EEAs) by the pattern of concentra-
tion-response curves. In the pilot HTS assay, in which compounds
were exposed to cells for 48 h, only four compounds demonstrated
concentration-curves fitting in class 2.2 (partial curve; r
2$0.9;
efficacy#80%) according to previously established criteria for
concentration-response curve analysis (Table S2) [23]. These
compounds were found to be fluorescent dyes: ruthenium red
(,533 nm) and reactive blue (,605 nm). Two additional
Figure 8. Concentration-response curve analysis of HTS assay for ASA to identify fluorescence and colorimetric compounds. In a
1,536-well plate with the SV40t cultured cells were positioned in the same format as previous assays. LOPAC library was dispensed prior to add
substrate/lysis buffer for ASA and after terminating the assay with stop reaction solution. Six compounds depicted in these panels showed increases
of the percentage of OD signal (relative to baseline mean of OD value from MLD patient cells). Four highest concentration of LOPAC (0.92, 4.5, 22.8
and 114.2 microM) were used are shown in log scale (in M). Full lines and squares points represent results from the assay in which LOPAC was added
just prior to starting ASA assay reaction (pre-ASA assay). Dotted lines and open triangles showed results from the assay in which LOPAC was added
after stopping ASA assay reaction (post-ASA assay).
doi:10.1371/journal.pone.0029504.g008
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Interestingly, the similar HTS assay, in which LOPAC was added
at the highest tested concentrations pre- and post-dispensing the
substrate/lysis buffer, was instrumental to screen for these and
other colorimetric and fluorescent compounds (Fig.7). Thus, in
addition to use the red-shifted wavelength [37], the assay in which
the small molecule library is dispensed post-ASA assay (Fig. 8) will
be crucial to exclude small molecules that produce OD increases
because of their fluorescent or colorimetric properties. At primary
screening, other compounds showed concentration-response
curves of class 2.4 (partial curve; r
2#0.9; efficacy Min-80%) with
mild enhancements of OD values (10–15%) (Fig.7E–H). Testing
these candidate compounds in primary cell lines from controls and
MLD patient (ASA-I179S) using the classical absorbance ASA
assay was essential to examine their effect on ASA activity and
exclude them from further studies (Fig.9). Thus, class 2.4
candidate compounds, which present partial concentration-
response curves with poor fit and low efficacy, are unlikely to be
regarded as potential ‘‘hits’’ in the developed HTS assay [23].
LOPAC was used to test the statistical robustness of the MLD
patient cell-based HTS assay for ASA. Three characteristics of this
HTS assay can explain the low ‘‘hit’’ rate of the HTS. First, the
cellular nature of the HTS assay, in which compounds with poor
cell permeability or cytotoxicity within the concentrations tested,
are eliminated already in the primary screening. Since the
selection of ‘‘hits’’ is based on detection of enhancements of
residual ASA-I179S activity in MLD patient cells, compounds that
are cytotoxic will present lower ASA activity and, consequently, no
concentration-response curves. In fact, two small molecules
showed concentration-response curves of class 2.4 due to their
fluorescent properties. In the validation assays, these compounds
reduced substantially the ASA activity of primary cells from
controls and MLD patient (Fig.9A and 9D). These compounds
were then shown to reduce cell viability in cytotoxicity assays
(Table S2). Second, the quantitative aspect of the cell-based HTS
assay allows selecting and clustering candidate small molecules
based on the hierarchical classification of concentration-response
curves already in the primary screening. In previous studies, small
molecules ‘‘hits’’ from primary screening assays were only
characterized as potential EEAs when tested in patient’s cultured
fibroblasts at different concentrations [6,7]. Third, using a longer
wavelength (.550 nm), as in the developed HTS assay, reduction
of the percentage of false-positives from small molecules carrying
native fluorescence is observed [37,38].
In summary, this study demonstrates that cell lines from patients
with a LSD can be used in a cell-based HTS assay against small
molecule collections (Fig.10). The SV40t fibroblast line from a
patient MLD conserved the relative residual ASA activity as
observed in primary cells from which they were derived from.
Taking advantage of the fluorescence properties of white solid-
bottom plates, a fluorescence-quench absorbance ASA assay was
developed using the robust and reliable colorimetric pNCS
substrate, whose product (pNC) acted as a ‘‘plate fluorescence
quencher’’. The implementation of the developed cell-based HTS
assay against larger and diverse small molecule libraries should
allow the identification of novel potential drugs for MLD, a
devastating neurodegenerative LSDs. This approach can be used
for several other LSDs and other genetic disorders, especially those
Figure 9. Characterization of candidate compounds in primary culture MLD patient and control cells. The six compounds with
concentration-response curves of classes 2.2 and 2.4 were used to treat primary MLD patient (ASA-I179S) and control cells (ASA-WT). The small
molecule concentrations used in this assay were within those used in the primary screening. No significant enhancement of residual ASA-I179S
enzymatic activity in MLD patient primary fibroblasts was observed. The small molecules tested where those with concentration-response curve of
class 2.2: JFD00244 (A); 6-OH-DL-Dopa (B) and class 2.4: methoxyverapamil HCl (C); DL-E-dihydrosphingosine (D), 6-OH-melatonin (E) and I-Me-
Tyrphostin AG 538 (F). Reduction of ASA activity in both controls (ASA-WT) and MLD patient fibroblasts (ASA-I179S) were noted as increased
concentrations of JFD00244 (A), DL-E-dihydrosphingosine (D) and methoxyverapamil HCl (C).
doi:10.1371/journal.pone.0029504.g009
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high-density microplates. The patient cell-based and quantitative
HTS assay here proposed creates a novel opportunity to identify
numerous small molecules, as several potential therapeutic targets
are accessible in this disease-cellular environment.
Materials and Methods
Cells, chemical reagents and equipments
Skin fibroblast lines from patients with MLD were obtained
from the cell bank at Kennedy Krieger Institute, Johns Hopkins
Medical Institutions. Written consents and assents approved by
Office of Human Subjects Research, Institutional Review Boards
Committee JHM-IRB 2 at Johns Hopkins University School of
Medicine were obtained. The study reported was also approved by
Institutional Review Boards Committee JHM-IRB X at Johns
Hopkins University School of Medicine. Synthetic substrate para-
nitrocatechol sulfate (pNCS) and standard p-nitrocatechol (pNC)
were purchased from Sigma-Aldrich Inc. and used for the ASA
assays. The following fluorescent substrates, all purchased from
Sigma-Aldrich Inc., 4-methylumbelliferyl-beta-D-galactopyrano-
side (MUbetaGal) and 4-methylumbelliferyl-(2-acetamido-2-de-
oxy)-beta-D-glucopyranoside (MUG) were used to assay beta-
galactosidase and total beta-hexosaminidase, respectively. Chem-
icals including sodium acetate, sodium chloride, sodium hydrox-
ide, sodium pyrophosphate (Na2P2O7), citric acid, sodium
phosphate dihydrate, Triton-X100 and human serum albumin
were all purchased by Sigma-Aldrich Inc. The protein assay kit
(Bradford assays) and protease inhibitor cocktail were purchased
from Thermo-Fisher Inc. N-Dodecanoyl-(N-lissamine rhodaminyl-
(12 aminododecanoyl)cerebroside 3-sulfate (NBD-sulfatide) used
for exogenous substrate cellular assays (Fig.2) was purchased from
Matreya Inc. Molecular kits for PCRs and reverse transcriptase-
PCRs were purchased from Invitrogen Inc. Specific oligonucleo-
tides for sequencing of ARSA genomic and cDNA were designed as
previously described [39] and synthesized and purchased from
Sigma-Aldrich and IDT Corp. The Library of Pharmacological
Active Compounds (LOPAC) used in the pilot screening was
received from Sigma-Aldrich Inc. LOPAC was diluted in dimethyl
sulfoxide (DMSO). The following microplates were used in ASA
assays: (i) 96-well transparent, cell culture treated plates (BD
Comp.); (ii) 384-well white solid-bottom, polystyrene, tissue culture
treated, flat and solid bottom plates (Greiner CellStarH); (iii) 384-
well black polystyrene, tissue culture treated, flat and transparent
bottom plates (Greiner CellStarH). The white solid-bottom and
black transparent-bottom 1,536-well plates (tissue culture treated
with flat bottom) were purchased from Greiner Bio-One. The
multi-well plate readers used were SpectraMAX 190 (absorbance
for 96-well plates) and SpectraMAX Gemini XS (fluorescence for
96- and 384-well plates) both from Molecular Devices
TM. Safire
2
(TECAN) mono-chromator based plate reader was used for
absorbance reading from 384-well plate. The pilot screening with
1,536-well plate was performed using the following equipments:
Thermo Scientific MultiDrop Combi - to seed cells into the plates;
Perkin Elmer 1430 ultraHTS Wallac Microplate Imager ViewLux
- for fluorescence reading in 1,536-well plate.
General Tissue Culture Conditions
Primary and transformed fibroblasts were cultured using
Dulbecco’s Modified Eagle Medium (DMEM; Medtech Inc.) with
and without phenol red containing 10% fetal calf serum (FCS;
Gemini Biologicals Inc.). No antibiotics were used in routine tissue
culture procedures. Cells were cultured using traditional tissue
culture incubators with 5% CO2 at 37uC. Cells were washed at
least twice in phosphate-saline buffer (PBS) before being harvest.
Cell lysates for ASA assays were obtained by re-suspending cells in
sodium acetate buffer (0.5 M) with protease inhibitors cocktail
(Thermo Fisher). Glycerol at 5% was added, as cells were lysate by
freeze-thaw method (,5 times) without the use of detergents.
Trypsin PBS solution (0.05%) was used to dissociate cells. Primary
and SV40 transformed fibroblast were cultured in 75 cm
2 flasks to
prepare cultured cells into the different microplates used in the
described assays.
Transformation of primary skin fibroblasts with SV40
large T antigen
Cultured primary skin fibroblasts were transformed using pSV3-
neo plasmid containing the simian virus (SV) 40 large T cell
antigen. The plasmid pSV3-neo (ATCC Inc.) has 8.60 kb size with
markers ampR, G418R, SV40 promoter, pBR322 early promoter,
and pMB1 replicon. Firstly, primary cells were cultured in 75 cm
2-
flasks, and once these flasks became confluent, cells were
dissociated using 0.05% trypsin. An average of 7610
6 cells in
DMEM medium containing 10% FCS were transfected with 30
microg pSV3 plasmid by electroporation using Gene Pulser Xcell
Electroporation Systems (Biorad Inc.). Cuvettes of 4 mm were
used for these experiments. Approximately 4–6 weeks were taken
to obtaining initial clones of SV40 transformed cells.
ASA assays in 384-well microplates
The 384-well white solid-bottom plates containing cultured
SV40t cells were utilized in the fluorescence-quench absorbance
Figure 10. Algorithm summarizing the developed patient cell-
based HTS assay for ASA.
doi:10.1371/journal.pone.0029504.g010
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clear-bottom plates were used to measure absorbance at 515 nm
in Safire
2 TECAN plate reader. Cells were initially cultured to
confluence in a 75 cm
2-flask and then dissociated with 0.05% of
trypsin, diluted in 10% FCS DMEM (non-phenol red) medium to
reach a concentration of ,2610
3 cells/microL. Twenty microL
were transferred per well in 384-well plates, which were then kept
overnight in at 37uC in a tissue culture 5% CO2 incubator. On
average 40610
3 cells were seeded in each well of 384-well plates.
Substrate buffer was prepared with pNCS at 15 mM on the same
sodium acetate buffer (0.5 M; pH 5.0) earlier described with
exception of adding TX-100 (1%) to promote cell lysis. A volume
of 40 microL of this substrate/lysis buffer was added per well, and
plates were then incubated at room temperature for 14 hs. In
order to stop the ASA enzymatic reaction, 50 microL of NaOH
1N (pH 10.5) were placed in each well. In 384-well white solid-
bottom plates, fluorescence was read at excitation 525 nm and
emission 595 nm using multi-well plate reader (Spectra Gemini
XS). The absolute fluorescence value obtained was converted to
optical density (OD), calculated as OD=2log(sample/blank), where
sample represents the signal obtained from a specific well
containing cells, culture medium and pNCS substrate buffer and
stop reaction solution; blank represents the mean from signals from
wells containing no cells, but only cultured medium, pNCS
substrate buffer and stop reaction solution. The inter-leaved 384-
well plate assays (Fig.4C and 4D) were performed as the assay
guidance manual from NIH Chemical Genomics Center.
ASA assays in 1,536-well plates
The miniaturization to 1,536-well plate was performed using
128.0/85MM, tissue culture, sterile Greiner white solid-bottom
plates. Only SV40t cells were cultured in 1,536-well plates. On
average 8610
6 cells were dispensed per well of white solid-bottom
1,536-well plates using Thermo Scientific MultiDrop Combi
(,volume of 4 microL). After 6–7 h, LOPAC compounds (46 nL)
were transferred via a Kalypsys Pin-Tool equipped with a 1,536-
pin array (V&P Scientific Palo Alto, CA). Substrate/lysis buffer as
described above, with exception of the pNCS concentration of
1 mM, was dispensed (4 microL) after plates were incubated at
37uC (CO2 5%) for 48 h. After substrate incubation for 14 h at
room temperature, 2 microL of stop solution of NaOH (10 N) was
added in each well and fluorescence was measured at excitation
525 nm and emission 598 nm using ViewLux (PerkinElmer).
Thermo Scientific Multidrop Combi was used to dispense
substrate/lysis and stop solution in 1,536-well plates in the HTS
ASA assay (Table 2).
Cell-based quantitative pilot qHTS assay
The Library of Pharmacologically Active Compounds (LO-
PAC), a collection of 1,280 pharmacological compounds from
Sigma- Aldrich Inc. was used to perform the HTS pilot assay. One
single 1,536-well plate was able to accommodate the entire
LOPAC library and necessary controls as depicted in figure 5A.
SV40t fibroblasts from a MLD patient (ASA-I179S) and control
(ASA-WT) lines were used. Seven different concentrations of
LOPAC library were chosen, ranging from 7610
23to1142mi-
croM. Five-fold dilutions from the highest concentration (114.2
microM) was performed to cover a wide range of concentrations
chosen based on previous qHTS assays [23]. One additional
1,536-well plate containing only dimethyl sulfoxide (DMSO) was
performed as control plate. Cells were then exposed for 48 h
treatment period with LOPAC compounds (one compound/well)
at the seven different concentrations. After treatment, substrate/
lysis buffer was dispensed in each well as above described and
depicted in Table 2 and figure 5.
Cell treatment with selected candidate small molecules
Primary cultured skin fibroblasts from control (ASA-WT) and a
MLD patient (ASA-I179S) were seeded into 96-well plates.
Candidate compounds presenting concentration-response curve
class 2.2 and 2.4 in primary screening were tested in primary cells.
These small molecules were purchased from Sigma-Aldrich Inc.
(6-OH-DL-dopamine, FW; methoxyverapamil hydrochloride, FW
521.09;) and Santa Cruz Biotechnology (6-hydroxymelatonin, FW
248.28; D-erythro-Sphingosine, dihydro-, FW 301.5; I-OMe-
Tyrphostin AG 538, FW 437.19; JFD00244, FW 478.54). All the
compounds were diluted in dimethyl sulfoxide (DMSO) initially to
reach working solutions at 18–20 mM concentrations. Cells were
grown to confluence in 96-well plate and then treated in 5
concentrations: 7.1, 14.3, 28.6, 57.1 and 114.2 microM in DMEM
with FCS at 10% for 5 days. After five days, culture medium was
removed and ASA assays were performed in 96-well plates (where
cells were cultured) using colorimetric pNCS. Absorbance was
measured at 515 nm as described in Supporting Information S1.
Other lysosomal enzyme assays
Measurements of total beta-hexosaminidase (Hex) and beta-
galactosidase activity were performed using cultured cell lysates as
previously described [6].
NBD-sulfatide and microscopy assays
Firstly, NBD-sulfatide was conjugated with fatty acid free
human albumin as previously described [18]. Fibroblast cells were
grown on 6-well plate over a coverslip to 70% confluence. Culture
medium was changed to DMEM without FCS but containing 10
nmoles of albumin-conjugated NBD-sulfatide for 24 h incubation
at 37uC and 5%CO2. Cells were then washed with PBS five times.
Coverslips with cells were then mounted into glass slides with
antifade solution from Prolong Gold (Invitrogen Inc.). Confocal
laser scanning microscopy on the Zeiss LSM 510 confocal system
was performed. All the images were taken using 40 and 60 X 1.4
numerical apertures with Apochromat objectives. Images were
performed using the Zeiss 2009 software.
Statistics
Where applicable, data are expressed as the mean 6 standard
deviation (S.D.). Comparisons of parametric data were analyzed in
the use of conventional parametric statistical methods as two-tail
Student’s t test. The statistical test Z’ factor was used to measure
the quality of the assay and its applicability to high throughput
screening [40]. Assays with Z’ factor of 0.5 indicate that the assay
robust enough to identify enhancement of enzyme activity reliably
[40]. Coefficient of variance (CV) and signal-to-noise ratios were
also calculated when comparing signals from ASA activity from
wild type (WT) and mutant (MUT) cell lines. Concentration curve
analysis was performed utilizing non-linear regression curve fit
using Prism version 5.0d.
Supporting Information
Supporting Information S1
(DOCX)
Figure S1 ASA throughput assay in 96-well plates. ASA
assays were performed initially in primary skin fibroblast cultured
in 96-well plates. (A) In a control primary skin fibroblasts (ASA-
WT), substrate pNCS concentrations were assessed. After reaching
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before substrate solution (pNCS 10 mM) was added. Blue bars
represent wells assayed (4/substrate concentration) and white bars,
the correspond blanks containing wells with cells treated the same
way but loaded stop solution before substrate buffer. (B) In the
plate uniformity assessment (inter-leaved signal format), ASA
activity was measured using pNCS (10 mM) from control
fibroblasts with ASA-WT (squares – maximum signal) and the
MLD patient fibroblasts with ASA-I179S (triangles – mid signal)
cultured in three 96-well plates, which were assayed in different
days. Background signal (minimum signal) was derived from wells
with cells but as previously the stop solution was added before
substrate solution (diamonds). The mean signal-to-noise ratio was
4.99+0.66 and 2.25+0.15 for the control (squares) and I179S
mutant (triangles) ASA cell lines, respectively. (C) DMSO
tolerance test showed that concentrations over 2% in the reaction
assay volume decreases the ASA activity against pNCS. (D)
Performing similar assays in 96-well plate, SV40-transformed
fibroblast from control (SV40t –CTRL) and MLD patient cells
(SV40t-MLD) showed increased absorbance signals correspondent
primary (prim) cell lines: prim-CTRL and prim-MLD. MLD
patient cell line tested carries mutation ASA-c.459+1G.A/
E482G, resulting in a lower ASA residual activity than ASA-
I179S.
(TIF)
Figure S2 Scatter plot from the quantitative cell-based
HTS assay for ASA using LOPAC. Panels represent SV40t
cells from control (ASA-WT) and MLD patient (ASA-I179S).
SV40t MLD patient cells were exposed to the 1,280 compounds
from LOPAC in different concentrations (panels A–E). OD signal
derived from MLD patient cells treated with LOPAC were located
in columns 5–44. Columns 2, 3, 46 and 47 represent OD signals
from wells contained control cells, which were not treated with
compounds. MLD patient fibroblasts treated only with DMSO
were located in columns 4 and 45. The small molecule
concentrations MLD patient cells were exposed to: 36610
23
microM (A), 0.18 microM (B), 0.9 microM (C), 4.5 microM (D)
and 22.8 microM (E). Scatter plot results from cells seeded in the
same manner but treated with DMSO and the highest (114.2
microM) and lowest (7610
23 microM) concentrations of LOPAC
are shown in Figure 6 (article).
(TIF)
Table S1 Curve classification of concentration-response
curves.
(DOCX)
Table S2 Cell viability assay for treatment of candidate
compounds from HTS.
(DOCX)
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